Plasma lipidome and risk of atrial fibrillation: results from the PREDIMED trial

Estefanía Toledo Atucha; Clemens Wittenbecher; Cristina Razquin Burillo; Miguel Ruiz-Canela López; Clary B. Clish; Liming Liang; Álvaro Alonso; Pablo Hernández Alonso; Nerea Becerra Tomás; Luis Fernando Aros Borau; Dolores Corella Piquer; Emilio Ros Rahola; Ramón Estruch Riba; Antonio García Rodríguez; Montserrat Fitó Colomer; José Lapetra Peralta; Miguel Fiol Sala; Ángel M. Alonso Gómez; Lluís Serra Majem; Amy Deik; Jordi Salas Salvadó; Frank Hu; Miguel Ángel Martínez González

Ayuda

Plasma lipidome and risk of atrial fibrillation: results from the PREDIMED trial

Toledo, Estefania ^[9] ; Wittenbecher, Clemens ^[1] ; Razquin, Cristina ^[9] ; Ruiz-Canela, Miguel ^[9] ; Clish, Clary B. ^[2] ; Liang, Liming ^[10] ; Alonso, Alvaro ^[3] ; Hernández-Alonso, Pablo ^[11] ; Becerra-Tomás, Nerea ^[12] ; Arós-Borau, Fernando ^[13] ; Corella, Dolores ^[4] ; Ros, Emilio ^[14] ; Estruch, Ramón ^[5] ; García-Rodríguez, Antonio ^[6] ; Fitó, Montserrat ^[7] ; Lapetra, José ^[8] ; Fiol, Miquel ^[15] ; Alonso-Gomez, Ángel M. ^[13] ; Serra-Majem, Luis ^[16] ; Deik, Amy ^[2] ; Salas-Salvadó, Jordi ^[17] ; Hu, Frank B. ^[18] ; Martínez-González, Miguel A. ^[19]
1. [1] Chalmers University of Technology
  
  Chalmers University of Technology
  
  Suecia
2. [2] Broad Institute
  
  Broad Institute
  
  City of Cambridge, Estados Unidos
3. [3] Emory University
  
  Emory University
  
  Estados Unidos
4. [4] Universitat de València
  
  Universitat de València
  
  Valencia, España
5. [5] Universitat de Barcelona
  
  Universitat de Barcelona
  
  Barcelona, España
6. [6] Universidad de Málaga
  
  Universidad de Málaga
  
  Málaga, España
7. [7] Medical Research Institute
  
  Medical Research Institute
  
  Sri Lanka
8. [8] Instituto de Salud Carlos III
  
  Instituto de Salud Carlos III
  
  Madrid, España
9. [9] Department of Preventive Medicine and Public Health, Edificio de Investigación, University of Navarra, Planta 2, Calle Irunlarrea 1, 31008, Pamplona, Spain ; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain ; CIBER Fisiopatología de La Obesidad Y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
10. [10] Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA
11. [11] CIBER Fisiopatología de La Obesidad Y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Departament de Bioquímica I Biotecnologia, Universitat Rovira I Virgili, Unitat de Nutrició Humana, Reus, Spain; Institut d’Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari San Joan de Reus, Reus, Spain; Unidad de Gestión Clínica de Endocrinología Y Nutrición del Hospital Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain
12. [12] Departament de Bioquímica I Biotecnologia, Universitat Rovira I Virgili, Unitat de Nutrició Humana, Reus, Spain; Institut d’Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari San Joan de Reus, Reus, Spain; Department of Preventive Medicine and Public Health, School of Medicine, University of Valencia, Valencia, Spain
13. [13] CIBER Fisiopatología de La Obesidad Y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Bioaraba Health Research Institute Osakidetza Basque Health Service, Araba University Hospital University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain
14. [14] CIBER Fisiopatología de La Obesidad Y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Endocrinology & Nutrition, Hospital Clinic, Barcelona, Spain
15. [15] CIBER Fisiopatología de La Obesidad Y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; IdISBa. Health Research Institute of the Balearis Islands, Palma, Spain
16. [16] CIBER Fisiopatología de La Obesidad Y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI) del Servicio Canario de Salud, Gobierno de Canarias, Las Palmas de Gran Canaria, Spain
17. [17] CIBER Fisiopatología de La Obesidad Y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Departament de Bioquímica I Biotecnologia, Universitat Rovira I Virgili, Unitat de Nutrició Humana, Reus, Spain; Institut d’Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari San Joan de Reus, Reus, Spain
18. [18] Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
19. [19] Department of Preventive Medicine and Public Health, Edificio de Investigación, University of Navarra, Planta 2, Calle Irunlarrea 1, 31008, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; CIBER Fisiopatología de La Obesidad Y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Mostrar afiliaciones +
Localización: Journal of physiology and biochemistry, ISSN-e 1877-8755, ISSN 1138-7548, Vol. 79, Nº. 2, 2023, págs. 355-364
Idioma: inglés
Enlaces
- Texto completo 1 (pdf) 2
Resumen
- AbstractThe potential role of the lipidome in atrial fibrillation (AF) development is still widely unknown. We aimed to assess the association between lipidome profiles of the Prevención con Dieta Mediterránea (PREDIMED) trial participants and incidence of AF. We conducted a nested case–control study (512 incident centrally adjudicated AF cases and 735 controls matched by age, sex, and center). Baseline plasma lipids were profiled using a Nexera X2 U-HPLC system coupled to an Exactive Plus orbitrap mass spectrometer. We estimated the association between 216 individual lipids and AF using multivariable conditional logistic regression and adjusted the p values for multiple testing. We also examined the joint association of lipid clusters with AF incidence. Hitherto, we estimated the lipidomics network, used machine learning to select important network-clusters and AF-predictive lipid patterns, and summarized the joint association of these lipid patterns weighted scores. Finally, we addressed the possible interaction by the randomized dietary intervention.Forty-one individual lipids were associated with AF at the nominal level (p < 0.05), but no longer after adjustment for multiple-testing. However, the network-based score identified with a robust data-driven lipid network showed a multivariable-adjusted ORper+1SD of 1.32 (95% confidence interval: 1.16–1.51; p < 0.001). The score included PC plasmalogens and PE plasmalogens, palmitoyl-EA, cholesterol, CE 16:0, PC 36:4;O, and TG 53:3. No interaction with the dietary intervention was found. A multilipid score, primarily made up of plasmalogens, was associated with an increased risk of AF. Future studies are needed to get further insights into the lipidome role on AF.Current Controlled Trials number, ISRCTN35739639.